Literature DB >> 22885886

Molecular immunology of allergic conjunctivitis.

Murat T Irkec1, Banu Bozkurt.   

Abstract

PURPOSE OF REVIEW: Successful treatment of allergic eye disease depends on understanding the pathophysiology of ocular allergy. Thus, in this review, recent experimental and clinical research that has provided significant information about the immunopathology of allergic eye disease will be discussed. RECENT
FINDINGS: Recently, role of various cells, cytokines and chemokines has been scrutinized in the immunopathogenesis of ocular allergy. In this respect, current research highlights contribution of special molecules and cells in the development and clinical features of immunoglobulin E (IgE) and T-cell-mediated eye allergies.
SUMMARY: Recent findings in molecular immunology of ocular allergy, which comprise complex inflammatory conditions of the conjunctiva, have enabled us to better understand the pathophysiology of these diseases and have aided in the potential development of new therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885886     DOI: 10.1097/ACI.0b013e328357a21b

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  11 in total

1.  Potential toxicity of topical ocular solutions.

Authors:  Nevio Cimolai
Journal:  CMAJ       Date:  2019-08-12       Impact factor: 8.262

2.  Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model.

Authors:  Hanna-Mari Jauhonen; Jarmo Laihia; Olli Oksala; Johanna Viiri; Reijo Sironen; Päivi Alajuuma; Kai Kaarniranta; Lasse Leino
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-24       Impact factor: 3.117

3.  DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs.

Authors:  Samantha Deianira Dattoli; Monica Baiula; Rossella De Marco; Andrea Bedini; Michele Anselmi; Luca Gentilucci; Santi Spampinato
Journal:  Br J Pharmacol       Date:  2018-09-17       Impact factor: 8.739

Review 4.  Ocular redness - I: Etiology, pathogenesis, and assessment of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Sonia Anchouche; Ann Yung; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-16       Impact factor: 6.268

5.  Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy.

Authors:  Monica Baiula; Andrea Bedini; Jacopo Baldi; Megan E Cavet; Paolo Govoni; Santi Spampinato
Journal:  Drug Des Devel Ther       Date:  2014-06-10       Impact factor: 4.162

6.  Context-Dependent Regulation of Conjunctival Goblet Cell Function by Allergic Mediators.

Authors:  Laura García-Posadas; Robin R Hodges; Yolanda Diebold; Darlene A Dartt
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

7.  Exposure to Traffic-Related Particulate Matter 2.5 Triggers Th2-Dominant Ocular Immune Response in a Murine Model.

Authors:  Hyun Soo Lee; Sehyun Han; Jeong-Won Seo; Ki-Joon Jeon
Journal:  Int J Environ Res Public Health       Date:  2020-04-24       Impact factor: 3.390

8.  Allergic conjunctivitis increases the likelihood of undergoing eyelid incision surgery in pediatric and adolescent patients.

Authors:  Li Lyung Wang; Ji-Won Kwon; Ju-Yeun Lee
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

Review 9.  Potential Biomarkers for Allergic Conjunctival Diseases.

Authors:  Neeta Roy; Shir Levanon; Penny A Asbell
Journal:  Eye Contact Lens       Date:  2020-03       Impact factor: 3.152

10.  Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief.

Authors:  Warner Carr; Jack Schaeffer; Eric Donnenfeld
Journal:  Allergy Rhinol (Providence)       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.